Abstract
Objectives: In resectable advanced laryngeal cancer, the locoregional control rate achieved with reduced intra-arterial cisplatin and concurrent radiotherapy (Kanazawa regimen) was comparable to that of the concurrent chemoradiotherapy arm of the Radiation Therapy Oncology Group study 91-11 with reduced toxicities. However, distant metastases were more frequent. This study retrospectively evaluated the efficacy and feasibility of adjuvant chemotherapy with TS-1®, an oral fluoropyrimidine, on distant metastases following the Kanazawa regimen.
Methods: Sixty-one patients treated with the Kanazawa regimen, who had achieved a complete response at the primary site, were analyzed. Following the Kanazawa regimen, twenty-four patients were administered TS-1® for 2 weeks, followed by 1-week rest, and the cycle was repeated for 6 months {TS-1(+) group}. Thirty-seven patients were not administered TS-1® {TS-1(-)group}.
Results: There were significant differences in distant metastases-free survival (p=0.015) and disease-free survival (p=0.046) in favor of the TS-1(+) group. Nineteen patients (79.2%) in the TS-1(+) group received TS-1® according to the planned schedule and dose. Grade 3 toxicities were observed in two patients (8.3%), but there was no grade 4 event.
Conclusions: In resectable advanced laryngeal cancer, TS-1® adjuvant chemotherapy is an effective and feasible treatment option to control distant metastases following the Kanazawa regimen.
